Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Status: Recruiting
DFCI Protocol ID: 17-513

Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with everolimus once daily to pediatric participants with recurrent/refractory solid tumors. Phase 2, utilizing Simon's optimal 2-stage design, will be conducted to estimate the antitumor activity of lenvatinib in combination with everolimus in pediatric participants with selected recurrent/refractory solid tumors including Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET), rhabdomyosarcoma, and high grade glioma (HGG) using objective response rate (ORR) at Week 16 as the outcome measure.

Conducting Institutions:

Brigham and Women's Hospital, Dana-Farber Cancer Institute

Overall PI:

Steven Dubois MD, Dana Farber Cancer Institute

Site-responsible Investigators:


Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP,

Eligibility Criteria

Inclusion Criteria

  -  2 years to 21 years of age

  -  Recurrent or refractory solid tumors

       -  Phase 1: All solid tumors (measurable or evaluable disease), including primary
  central nervous system (CNS) tumors; exclusion of hepatoblastoma and lymphomas

       -  Phase 2: Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET),
  Rhabdomyosarcoma, High Grade Glioma (HGG) (all must have measurable disease);
  exclusion of Diffuse Intrinsic Pontine Glioma

  -  Histologically or cytologically confirmed diagnosis

  -  Karnofsky performance score ≥50 for participants>16 year of age and Lansky play score
     ≥50 for participants ≤16 years of age. Neurologic deficits in participants with CNS
     tumors must have been relatively stable for at least 7 days prior to study enrollment.
     Participants who are unable to walk because of paralysis, but who are up in a
     wheelchair, will be considered ambulatory for the purpose of assessing the performance

  -  Prior Therapy

       -  Participants must have fully recovered from the acute toxic effects of all prior
  anti-cancer therapy

       -  Cytotoxic chemotherapy or other chemotherapy known to be myelosuppressive: ≥21
  days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days
  if prior nitrosourea)

       -  Anti-cancer agents not known to be myelosuppressive (eg, not associated with
  reduced platelet or absolute neutrophil counts): ≥7 days after the last dose of

       -  Monoclonal antibodies: ≥21 days or 3 half-lives (whichever is shorter) of the
  antibody must have elapsed after the last dose of a monoclonal antibody
  (including checkpoint inhibitors). Toxicity related to prior antibody therapy
  must be recovered to Grade ≤1

       -  Corticosteroids: If used to modify immune adverse events related to prior
  therapy, ≥14 days must have elapsed since last dose of corticosteroid.
  Participants receiving corticosteroids, who have not been on a stable or
  decreasing dose of corticosteroid for at least 7 days prior to enrollment, are
  not eligible

       -  Hematopoietic growth factors: ≥14 days after the last dose of a long-acting
  growth factor or 7 days for short-acting growth factor. For agents that have
  known adverse events occurring beyond 7 days after administration, this period
  must be extended beyond the time during which adverse events are known to occur

       -  Interleukins, interferons, and cytokines (other than hematopoietic growth
  factors): ≥21 days after the completion of interleukins, interferons or cytokines
  (other than hematopoietic growth factors)

       -  Stem cell infusions (with or without total body irradiation): Allogeneic
  (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion
  including donor leukocytes infusion or boost infusion: ≥84 days after infusion
  and no evidence of graft versus host disease; Autologous stem cell infusion
  including boost infusion: ≥42 days

       -  Cellular Therapy: ≥42 days after the completion of any type of cellular therapy
  (eg, modified T cells, natural killer cells, dendritic cells, etc)

       -  Radiotherapy (XRT)/External Beam Irradiation including Protons: ≥14 days after
  local XRT; ≥150 days after total body irradiation, craniospinal XRT or if
  radiation to ≥50% of the pelvis; ≥42 days if other substantial bone marrow

       -  Radiopharmaceutical therapy: ≥42 days after systemically administered therapy.

       -  Vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-targeted or
  mammalian target of rapamycin (mTOR)-targeted therapies: Must not have received
  prior exposure to lenvatinib; May have previously progressed on an mTOR
  inhibitor; No more than 2 prior VEGF/VEGFR-targeted therapies (For Phase 2 only);
  Must not have received prior VEGF/VEGFR-targeted therapy in combination with an
  mTOR inhibitor (For Phase 2 only)

  -  Adequate bone marrow function for participants with solid tumors without known bone
     marrow involvement

  -  Adequate bone marrow function for participants with known bone marrow metastatic

  -  Adequate renal function

  -  Adequate liver function

  -  Adequate cardiac function

  -  Adequate neurologic function

  -  Adequate blood pressure (BP) control with or without antihypertensive medications

  -  Adequate coagulation

  -  Adequate pancreatic function

  -  Participants must have a minimum body surface area (BSA) of 0.6 m^2 at study entry,
     with the exception of one study arm which requires a minimum BSA of 1.33 m^2.

Exclusion Criteria

  -  Participants who have had or are planning to have the following invasive procedures

       -  Major surgical procedure, laparoscopic procedure, open biopsy or significant
  traumatic injury within 28 days prior to enrollment

       -  Central line placement or subcutaneous port placement is not considered major
  surgery. External central lines must be placed at least 3 days prior to
  enrollment and subcutaneous ports must be placed at least 7 days prior to

       -  Fine needle aspirate within 7 days prior to enrollment.

       -  Surgical or other wounds must be adequately healed prior to enrollment.

       -  For purposes of this study, bone marrow aspirate and biopsy are not considered
  surgical procedures and therefore are permitted within 14 days prior to start of
  protocol therapy

  -  Participants who have non-healing wound, unhealed or incompletely healed fracture, or
     a compound (open) bone fracture at the time of enrollment

  -  Clinical evidence of nephrotic syndrome prior to enrollment

  -  Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half
     teaspoon) within 21 days prior to enrollment

  -  Thrombotic/ thromboembolic event requiring systemic anticoagulation within 90 days
     prior to enrollment

  -  Evidence of new intracranial hemorrhage of more than punctate size on MRI assessment
     obtained within 28 days prior to study enrollment for Participants with HGG

  -  Diagnosis of lymphoma

  -  Radiographic evidence of major blood vessel invasion/infiltration.

  -  Evidence of untreated CNS metastases

  -  Participants who are currently receiving enzyme-inducing anticonvulsants

  -  Participants chronically receiving strong cytochrome P450 3A4 (CYP3A4)/P-glycoprotein
     (P-gp) inhibitors or inducers within 7 days prior to study enrollment

  -  Females who are breastfeeding or pregnant. For females of childbearing potential, a
     negative screening pregnancy test must be obtained within 72 hours before the first
     dose of study drug

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.